A Multidisciplinary Approach to CAR T-cell Therapy for Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Episode 7
Considerations Regarding Bridging Therapy for B-ALL CAR T-Cell Treatment
Experts discuss the routine initiation of bridging therapy between leukapheresis and chimeric antigen receptor (CAR) T-cell infusion at their center; the pharmacist’s role in implementing this procedure; collaboration with the team on agent choice, dosage, and administration; and monitoring for disease control and adverse events as well as the observed impact of bridging therapy on outcomes post CAR T-cell therapy.
Video Player is loading.
Video content above is prompted by the following:
At your center, is bridging therapy routinely initiated during the interval between leukapheresis and CAR T-cell infusion?
- If so, as a pharmacist, what is your role in implementing this procedure?
- With whom on the team do you communicate on choice of agent, dosage, administration frequency, and monitoring for disease control and adverse events?
- What impact of bridging therapy have you observed on outcomes post CAR T-cell therapy?
